Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation.
Pre-bronchodilator FEV1 \>75% of predicted at screening.
Non-smoker
Demonstration of a positive reaction to at least one allergen from a battery of allergens (including house dust mite, grass pollen and cat hair on skin prick testing at screening, or within 12 months of study start.
Have Asthmatic response
Able and willing to give written informed consent to take part in the study.
Available to complete all study measurements.
You may not be if
History of cardiovascular disease
Clinically significant abnormalities in safety laboratory analysis at screening including any subject who has greater than "trace urine protein levels" following urinalysis at screening.
History of hayfever
The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
The subject has tested positive for HIV antibodies.
The subject has positive drugs of abuse test.
Subjects weighing less than 50kg are to be excluded from participating in the study.
The subject has participated in a study with a new molecular entity during the previous 3 months.
History of being unable to tolerate or complete methacholine, and/or allergen challenge tests.
There is a risk of non-compliance with study medication or study procedures.
History of blood donation (450 mL) within 2 months of starting the clinical study.
The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (24 ml) of spirits.
